ArticleScience progress
The impact of long noncoding RNA LINKA on the GPNMB/HIF-1α signaling pathway in hyperoxic acute lung injury.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the role and mechanism of long noncoding RNA LINKA (LncRNA LINKA) in hyperoxia-induced acute lung injury (HALI), specifically focusing on its impact on the GPNMB (glycoprotein nonmetastatic B protein)/HIF-1α (hypoxia-inducible factor 1-alpha) signaling pathway of apoptosis.MethodsAn experimental animal study was conducted using specific pathogen-free (SPF) male C57BL/6 mice and GPNMB knockout (KO) mice. Lung injury was assessed by measuring total protein in bronchoalveolar lavage fluid (BALF), lung wet/dry weight (W/D) ratio, serum levels of inflammatory (tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)) and oxidative stress (malondialdehyde (MDA) and superoxide dismutase (SOD)) mediators, histopathological scoring (hematoxylin and eosin staining), apoptosis rate (terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay), and expression levels of GPNMB/HIF-1α pathway proteins (p-GPNMB, phosphorylated leucine-rich repeat kinase 2 (p-LRRK2), p-HIF-1α) and apoptosis regulators (BCL2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2)) via western blotting.ResultsOverexpression of LncRNA LINKA significantly mitigated HALI in mice, evidenced by: reduced total protein in BALF; decreased lung W/D ratio (indicating attenuated pulmonary edema); lower serum levels of TNF-α, IL-1β, and MDA, and higher SOD; improved lung histopathology with reduced inflammatory cell infiltration and alveolar septal thickening; and decreased apoptosis rate. Conversely, silencing LncRNA LINKA exacerbated HALI. Mechanistically, LncRNA LINKA overexpression increased phosphorylation of GPNMB, LRRK2, and HIF-1α, upregulated antiapoptotic Bcl-2, and downregulated pro-apoptotic Bax. Crucially, these protective effects and pathway activation were abolished in GPNMB KO mice.ConclusionsLncRNA LINKA may protect against HALI by activating the GPNMB/HIF-1α signaling pathway, leading to suppressed apoptosis and inflammation. This identifies LncRNA LINKA as a potential therapeutic target for HALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.